The Genetic Landscape and Epidemiology of Phenylketonuria.
Alicia Hillert,Yair Anikster,Amaya Belanger-Quintana,Alberto Burlina,Barbara K. Burton,Carla Carducci,Ana E. Chiesa,John Christodoulou,Maja Dordevic,Lourdes R. Desviat,Aviva Eliyahu,Roeland A. F. Evers,Lena Fajkusova,Francois Feillet,Pedro E. Bonfim-Freitas,Maria Gizewska,Polina Gundorova,Daniela Karall,Katya Kneller,Sergey Kutsev,Vincenzo Leuzzi,Harvey L. Levy,Uta Lichter-Konecki,Ania C. Muntau,Fares Namour,Mariusz Oltarzewski,Andrea Paras,Belen Perez,Emil Polak,Alexander Polyakov,Francesco Porta,Marianne Rohrbach,Sabine Scholl-Burgi,Norma Specola,Maja Stojiljkovic,Nan Shen,Luiz C. Santana-da Silva,Anastasia Skouma,Francjan van Spronsen,Vera Stoppioni,Beat Thony,Friedrich K. Trefz,Jerry Vockley,Youngguo Yu,Johannes Zschocke,Georg F. Hoffmann,Sven F. Garbade,Nenad Blau
DOI: https://doi.org/10.1016/j.ajhg.2020.06.006
2020-01-01
Abstract:Phenylketonuria (PKU), caused by variants in the phenylalanine hydroxylase (PAH) gene, is the most common autosomal-recessive Mendelian phenotype of amino acid metabolism. We estimated that globally 0.45 million individuals have PKU, with global prevalence 1:23,930 live births (range 1:4,500 [Italy]-1:125,000 [Japan]). Comparing genotypes and metabolic phenotypes from 16,092 affected subjects revealed differences in disease severity in 51 countries from 17 world regions, with the global phenotype distribution of 62% classic PKU, 22% mild PKU, and 16% mild hyperphenylalaninemia. A gradient in genotype and phenotype distribution exists across Europe, from classic PKU in the east to mild PKU in the southwest and mild hyperphenylalaninemia in the south. The c.1241A>G (p.Tyr414Cys)-associated genotype can be traced from Northern to Western Europe, from Sweden via Norway, to Denmark, to the Netherlands. The frequency of classic PKU increases from Europe (56%) via Middle East (71%) to Australia (80%). Of 758 PAH variants, c.1222C>T (p.Arg408Trp) (22.2%), c.1066-11G>A (IVS10-11G>A) (6.4%), and c.782G>A (p.Arg261Gln) (5.5%) were most common and responsible for two prevalent genotypes: p.[Arg408Trp];[Arg408Trp] (11.4%) and c.[1066-11G>A];[1066-11G>A] (2.6%). Most genotypes (73%) were compound heterozygous, 27% were homozygous, and 55% of 3,659 different genotypes occurred in only a single individual. PAH variants were scored using an allelic phenotype value and correlated with pre-treatment blood phenylalanine concentrations (n = 6,115) and tetrahydrobiopterin loading test results (n = 4,381), enabling prediction of both a genotype-based phenotype (88%) and tetrahydrobiopterin responsiveness (83%). This study shows that large genotype databases enable accurate phenotype prediction, allowing appropriate targeting of therapies to optimize clinical outcome.